Santen Pharmaceutical Co., Ltd.
SNPHF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $467 | $68,737 | $77,231 | $76,369 |
| % Growth | -99.3% | -11% | 1.1% | – |
| Cost of Goods Sold | $212 | $31,619 | $31,135 | $34,135 |
| Gross Profit | $256 | $37,118 | $46,096 | $42,234 |
| % Margin | 54.7% | 54% | 59.7% | 55.3% |
| R&D Expenses | $42 | $6,207 | $7,330 | $5,829 |
| G&A Expenses | $0 | $0 | $1,399 | $0 |
| SG&A Expenses | $144 | $21,204 | $22,565 | $22,488 |
| Sales & Mktg Exp. | $0 | $0 | $17,410 | $0 |
| Other Operating Expenses | $0 | $2,134 | $6,338 | $2,134 |
| Operating Expenses | $186 | $29,545 | $36,233 | $30,451 |
| Operating Income | $70 | $7,573 | $9,863 | $11,783 |
| % Margin | 14.9% | 11% | 12.8% | 15.4% |
| Other Income/Exp. Net | -$1 | -$123 | $2,309 | -$313 |
| Pre-Tax Income | $69 | $7,450 | $12,172 | $11,470 |
| Tax Expense | $15 | $1,587 | $3,667 | $2,826 |
| Net Income | $54 | $5,878 | $8,791 | $8,693 |
| % Margin | 11.7% | 8.6% | 11.4% | 11.4% |
| EPS | 0.17 | 17.33 | 25.74 | 25.32 |
| % Growth | -99% | -32.7% | 1.7% | – |
| EPS Diluted | 0.16 | 17.28 | 25.69 | 25.22 |
| Weighted Avg Shares Out | 330 | 340 | 342 | 345 |
| Weighted Avg Shares Out Dil | 340 | 340 | 341 | 345 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $0 | $1,173 | $148 |
| Interest Expense | $3 | $122 | $0 | $0 |
| Depreciation & Amortization | $32 | $4,497 | $4,399 | $4,507 |
| EBITDA | $103 | $12,070 | $18,485 | $15,830 |
| % Margin | 22.1% | 17.6% | 23.9% | 20.7% |